Mentatcurated
Product

VERVE-102

Single-dose in vivo base editing therapy that permanently inactivates PCSK9 in the liver to lower LDL cholesterol, developed by Verve Therapeutics and now owned by Eli Lilly.

1 find · high confidence
MakerEli Lilly (acquired Verve Therapeutics)
Categorygene therapy / cardiovascular medicine
Reviewed2026-06-09
Visit www.vervetx.com/our-programs/verve-102 →

The lenses

Scored on its own merits — not rolled up from the finds we publish.

Novelty 4
Impact · breadth 4
Impact · depth 4
Actionable 1
Substance 4
Hype 3

Active in

Related concepts

How this connects

Tap a node to open it